Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


No New Trials, Omapro "Complete Response" Says, But Diagnostic Is Desired

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Australian-headquartered ChemGenex received a "complete response" letter from FDA for its new drug application for Omapro (omacetaxine mepesuccinate) for chronic myeloid leukemia, and the company is breathing a sigh of relief that it will not have to conduct additional trials or enroll additional patients, the company said April 12

You may also be interested in...

U.S. FDA Says Australian ChemGenex Needs Companion Diagnostic For Omapro

Australian-headquartered ChemGenex has agreed to meet with U.S. FDA in April to begin developing a validated assay test for determining which patients might benefit from its experimental chronic myeloid leukemia treatment Omapro.

Omapro Needs Companion Diagnostic, Advisory Committee Says

ChemGenex must determine which chronic myeloid leukemia patients have the T351I mutation and could benefit from the drug.

Australian ChemGenex's Omapro Faces Scaled Back Efficacy Claims After Trial Shortcomings

After a snow delay in Washington, Australian-headquartered ChemGenex now has more time to prepare for what will likely be a challenging review of Omapro (omacetaxine mepesuccinate) by U.S. FDA's Oncologic Drugs Advisory Committee


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts